MGA271

BIOLOGICAL2 trials

Sponsors

MacroGenics

Conditions

Bladder CancerHead and Neck CancerMelanomaNon-small Cell Lung CancerProstate CancerRenal Cell CarcinomaTriple-negative Breast Cancer

Phase 1

Safety Study of MGA271 in Refractory Cancer

CompletedNCT01391143

MacroGenicsBladder Cancer, Head and Neck Cancer, Melanoma +4

Start: 2011-07-31End: 2019-04-18Updated: 2022-02-08

Tissue Procurement Substudy for Participants in Study CP-MGA271-01

TerminatedNCT01918930

MacroGenicsMelanoma

Start: 2013-07-31End: 2016-10-31Updated: 2022-02-08